Breaking Finance News

Zacks Investment Research downgraded Trinity Biotech plc (ADR) (NASDAQ:TRIB) to Sell in a report released today.

Yesterday Trinity Biotech plc (ADR) (NASDAQ:TRIB) traded 3.80% higher at $6.31. The company’s 50-day moving average is $12.37 and its 200-day moving average is $11.72. The last stock close price is down -44.11% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 794,406 shares of the stock were exchanged, up from an average trading volume of 210,618

Zacks Investment Research has downgraded Trinity Biotech plc (ADR) (NASDAQ:TRIB) to Sell in a report released on 10/07/2016.

See Chart Below

Trinity Biotech plc (ADR) (NASDAQ:TRIB)

Trinity Biotech plc (ADR) has a 52 week low of $5.76 and a 52 week high of $13.68 with a P/E ratio of 27.87 The company’s market cap is currently $0.

About Trinity Biotech plc (ADR) (NASDAQ:TRIB)

Trinity Biotech plc (Trinity Biotech) develops, acquires, manufactures and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market. The Company's products are used to detect autoimmune, infectious and sexually transmitted diseases, diabetes, and disorders of the liver and intestine. It operates through two segments: the Americas and Rest of World. Its products are classified as POC, emergency medicine, clinical laboratory and blood bank screening. Its POC brands include Uni-Gold and Recombigen. Emergency medicine diagnostics refer to its acute care testing, STAT labs, pre/post-operative units, physician office labs and the central laboratory. Trinity Biotech supplies clinical laboratory market with reagent products and other products through its clinical chemistry business. Trinity Biotech's blood bank screening business unit manufactures products to screen donated blood for transfusion-transmissible infections.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *